| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| I420259-1ml |
1ml |
现货  |
|
| 别名 | 盐酸伊立替康 | (S)-4,11-二乙基-3,4,12,14-四氢-4-羟基-3,14-二氧代-1H-吡喃并[3',4':6,7]中氮茚并[1,2-b]喹啉-9-基酯 | CPT-11, [1,4'-联吡啶]-1'-羧酸 |
|---|---|
| 英文别名 | Irinotecan hydrochloride | 100286-90-6 | Irinotecan Hcl | Topotecin | Campto | Camptothecin 11 hydrochloride | Camptosar | CPT 11 | CPT-11 | Camptothecin 11 | Irinotecan (hydrochloride) | U 101440E | UNII-06X131E4OE | CHEBI:5971 | DTXSID6045953 | 06X131E4OE | (S)-4,11-diethyl-4-hydroxy- |
| 规格或纯度 | 10mM in DMSO |
| 英文名称 | Irinotecan hydrochloride |
| 生化机理 | 抗癌药伊立替康是一种前药，在组织羧酸酯酶作用下转化为7-乙基-10-羟基喜树碱（SN-38）——一种有效的DNA拓扑异构酶I抑制剂。通过UDP葡萄糖醛酸转移酶的葡萄糖醛酸化作用，可终止该药的作用。 抗癌药伊立替康是一种前药，在组织羧酸酯酶作用下转化为7-乙基-10-羟基喜树碱（SN-38）——一种有效的DNA拓扑异构酶I抑制剂。通过UDP葡萄糖醛酸转移酶1A1（UGT1A1）的葡萄糖醛酸化作用，可终止该药的作用。该药物能增强组织对辐射损伤的敏感性，因此可用于肿瘤的放射治疗。强大的DNA拓扑异构酶I抑制剂。显示针对多种肿瘤的抗肿瘤活性。也提供活性代谢物SN38。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
依立替康，能被组织羧酸酯酶转化为7 -乙基- 10 -羟基喜树碱（Sn - 38），该产物是一种强力的DNA拓扑异构酶I抑制剂。它的行动是由UDP葡萄糖醛酸转移酶1A1 (UGT1A1). 的葡萄糖醛酸化而终止。 盐酸伊立替康已使用于： •与5-氟尿嘧啶联用，筛选MDA-MB-231乳腺癌细胞中的生长抑制功能。 •在对高级别阑尾（HGA）和低级别阑尾（LGA）类器官的化学敏感性筛选中。 •与HT29结肠癌细胞中的热休克蛋白抑制剂（HPSC1）结合用作细胞毒性研究中的化学治疗剂。 Irinotecan hydrochloride has been used: • in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells. • in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids. • as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells. |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride |
| INCHI | 1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1 |
| InChi Key | GURKHSYORGJETM-WAQYZQTGSA-N |
| Smiles | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl |
| Isomeric SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl |
| 分子量 | 623.14 |
| Reaxy-Rn | 25807387 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=25807387&ln= |
| 敏感性 | 对热敏感 |
|---|---|
| 分子量 | 623.100 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 622.256 Da |
| 单同位素质量Monoisotopic Mass | 622.256 Da |
| 拓扑极表面积Topological Polar Surface Area | 113.000 Ų |
| 重原子数Heavy Atom Count | 44 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1200.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P330: 漱口 P301+P312: 如误吞咽：如感觉不适，呼叫急救中心/医生。 P501: 将内容物/容器处理到。。。 |
| WGK Germany | 3 |
| 1. Jia Cui, Ziyi Zhang, Han Zhong, Tao Zhang. (2023) Phosphorylcholine-grafted graphene oxide loaded with irinotecan for potential oncology therapy. RSC Advances, 13 (41): (28642-28651). [PMID:37790105] [10.1039/D3RA04987F] |
| 2. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo. (2023) Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels. JOURNAL OF CONTROLLED RELEASE, 360 (433). [PMID:37422124] [10.1016/j.jconrel.2023.07.003] |
| 3. Tan Xi, Wang Chenhui, Zhou Hong, Zhang Shuting, Liu Xuhan, Yang Xiangliang, Liu Wei. (2023) Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma. JOURNAL OF NANOBIOTECHNOLOGY, 21 (1): (1-15). [PMID:37291573] [10.1186/s12951-023-01950-y] |
| 4. Fei Wang, Xuyang Li, Xialin Hu, Wenya Zhuang, Jiewei Lai, Wenchao Wang, Xuanrong Sun, Hong Wang, Qingyong Li. (2022) Preparation and evaluation of camptothecin analogues-loaded lyophilization using Kolliphor® HS 15 as carrier. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 77 (103898). [10.1016/j.jddst.2022.103898] |
| 5. Wang Yi, Wang Wenchao, Yu Endian, Zhuang Wenya, Sun Xuanrong, Wang Hong, Li Qingyong. (2022) Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability. JOURNAL OF NANOBIOTECHNOLOGY, 20 (1): (1-15). [PMID:36064403] [10.1186/s12951-022-01596-2] |
| 6. Xuanrong Sun, Yubei Gong, Ting Xie, Zixi Fu, Dongze Lu, Bin Wei, Yue Cai, Wenlong Yao, Jie Shen. (2024) Nanoscale Liposomes Co-Loaded with Irinotecan Hydrochloride and Thalidomide for Colorectal Cancer Synergistic Therapy. MACROMOLECULAR BIOSCIENCE, (2400478). [PMID:39704649] [10.1002/mabi.202400478] |
| 7. Wang Yuhe, Li Junfeng, Li Xuanda, Gao Bingmiao, Chen Jiao, Song Yun. (2025) Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin. Scientific Reports, 15 (1): (1-16). [PMID:40055448] [10.1038/s41598-025-92607-3] |
首页
400-620-6333
7篇引用文献 
